Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34 Filing Table of Contents
Document/ExhibitDescriptionPagesSize
1: 10-Q Oncocyte Corporation 10-Q 6-30-2016 HTML 184K
2: EX-10.1 Material Contract HTML 25K
3: EX-31 Certification -- §302 - SOA'02 HTML 23K
4: EX-32 Certification -- §906 - SOA'02 HTML 14K
11: R1 Document and Entity Information HTML 38K
12: R2 Condensed Balance Sheets (Unaudited) HTML 85K
13: R3 Condensed Balance Sheets (Unaudited) HTML 32K
(Parenthetical)
14: R4 Condensed Statements of Operations (Unaudited) HTML 38K
15: R5 Condensed Statements of Comprehensive Loss HTML 26K
(Unaudited)
16: R6 Condensed Statements of Cash Flows (Unaudited) HTML 74K
17: R7 Organization, Basis of Presentation and Liquidity HTML 25K
18: R8 Summary of Significant Accounting Policies HTML 27K
19: R9 Selected Balance Sheet Components HTML 42K
20: R10 Related Party Transactions HTML 24K
21: R11 Shareholders' Equity HTML 22K
22: R12 Stock-based Compensation HTML 48K
23: R13 Income Taxes HTML 18K
24: R14 Commitments and Contingencies HTML 23K
25: R15 Organization, Basis of Presentation and Liquidity HTML 23K
(Policies)
26: R16 Summary of Significant Accounting Policies HTML 29K
(Policies)
27: R17 Summary of Significant Accounting Policies HTML 27K
(Tables)
28: R18 Selected Balance Sheet Components (Tables) HTML 47K
29: R19 Stock-based Compensation (Tables) HTML 49K
30: R20 Organization, Basis of Presentation and Liquidity HTML 30K
(Details)
31: R21 Summary of Significant Accounting Policies HTML 30K
(Details)
32: R22 Selected Balance Sheet Components (Details) HTML 69K
33: R23 Related Party Transactions (Details) HTML 33K
34: R24 Shareholders' Equity (Details) HTML 32K
35: R25 Stock-based Compensation (Details) HTML 85K
36: R26 Commitments and Contingencies (Details) HTML 38K
38: XML IDEA XML File -- Filing Summary XML 62K
37: EXCEL IDEA Workbook of Financial Reports XLSX 34K
5: EX-101.INS XBRL Instance -- ocx-20160630 XML 405K
7: EX-101.CAL XBRL Calculations -- ocx-20160630_cal XML 94K
8: EX-101.DEF XBRL Definitions -- ocx-20160630_def XML 195K
9: EX-101.LAB XBRL Labels -- ocx-20160630_lab XML 730K
10: EX-101.PRE XBRL Presentations -- ocx-20160630_pre XML 414K
6: EX-101.SCH XBRL Schema -- ocx-20160630 XSD 69K
39: ZIP XBRL Zipped Folder -- 0001140361-16-075892-xbrl Zip 68K
1. I have reviewed this quarterly report on Form 10-Q of OncoCyte Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this periodic report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
1. I have reviewed this quarterly report on Form 10-Q of OncoCyte Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this periodic report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
